Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice.

PLoS One · 2019 · PMC6326493 · PMID 30625213

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendP = 0.067so close (0.05 < p ≤ 0.1)

Comparison of the PFS between the T790M-loss group and the T790M-persistent group showed a trend toward worse PFS in the T790M-loss group (4.4 vs. 7.7 months, P = 0.067) ( Fig 5 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.